BioWorld

March 9, 2009

Roche Ups Offer for Genentech; Will $93 Per Share Get it Done?

After failing to tempt Genentech Inc.'s investors into tendering their shares for $86.50 a piece, Roche Holdings AG has upped its offer price to $93 per share. (BioWorld Today) Read More

AEterna Partners with Sanofi in $165M Deal for BPH Drug

Surface Logix Gets $20M Series E, Starts Phase IIb in Dyslipidemia

Washington Actions Loaded with Implications for Biotech

Early Data Put Kibosh on Opko's Bevasiranib Trial

Appointments And Advancements

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...